Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2137


Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.


Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.

Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K.

BJU Int. 2006 Jun;97(6):1184-9.


Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.

Soga N, Arima K, Sugimura Y.

Jpn J Clin Oncol. 2008 Sep;38(9):617-22. doi: 10.1093/jjco/hyn071. Epub 2008 Aug 12.


Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.

Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T; Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.

J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17.


A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.

Chu FM, Sartor O, Gomella L, Rudo T, Somerville MC, Hereghty B, Manyak MJ.

Eur J Cancer. 2015 Aug;51(12):1555-69. doi: 10.1016/j.ejca.2015.04.028. Epub 2015 Jun 2.


Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, Morganstern DE, Kantoff PW, Taplin ME.

Urology. 2013 Mar;81(3):611-6. doi: 10.1016/j.urology.2012.12.025.


Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.

Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y; Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer.

Cancer. 2009 Aug 1;115(15):3437-45. doi: 10.1002/cncr.24395.


An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.

Klotz L, Drachenberg D, Singal R, Aprikian A, Fradet Y, Kebabdjian M, Zarenda M, Chin J.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):320-4. doi: 10.1038/pcan.2014.24. Epub 2014 Sep 2.


Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience.

Kobayashi M, Nukui A, Suzuki K, Kurokawa S, Morita T.

Int J Clin Oncol. 2011 Dec;16(6):630-6. doi: 10.1007/s10147-011-0232-4. Epub 2011 Apr 23.


The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.

Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.

Jpn J Clin Oncol. 2012 Jun;42(6):534-40. doi: 10.1093/jjco/hys037. Epub 2012 Mar 20.


The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.

See WA, Tyrrell CJ; CASODEX Early Prostate Cancer Trialists' Group.

J Cancer Res Clin Oncol. 2006 Aug;132 Suppl 1:S7-16.


Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.

J Urol. 2007 Oct;178(4 Pt 1):1290-5. Epub 2007 Aug 14.


Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.

Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME.

BJU Int. 2012 Dec;110(11):1729-35. doi: 10.1111/j.1464-410X.2012.11456.x. Epub 2012 Aug 29.


Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade.

Martin NE, Chen MH, Nguyen PL, Beard CJ, Loffredo MJ, Kantoff PW, D'Amico AV.

BJU Int. 2012 Nov;110(9):1252-6. doi: 10.1111/j.1464-410X.2012.11118.x. Epub 2012 May 4.


Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.

Hussain A, Dawson N, Amin P, Naslund M, Engstrom C, Chen T.

Semin Oncol. 2001 Aug;28(4 Suppl 15):22-31.


Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.

Nishimura K, Arichi N, Tokugawa S, Yoshioka I, Kishikawa H, Ichikawa Y.

Int J Urol. 2007 Mar;14(3):264-7.


Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?

Labrie F, Candas B, Gomez JL, Cusan L.

Urology. 2002 Jul;60(1):115-9.


Supplemental Content

Support Center